Seoul Pharma Co. Ltd - Asset Resilience Ratio
Seoul Pharma Co. Ltd (018680) has an Asset Resilience Ratio of 9.30% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Seoul Pharma Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Seoul Pharma Co. Ltd's Asset Resilience Ratio has changed over time. See 018680 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Seoul Pharma Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Seoul Pharma Co. Ltd (018680) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩5.66 Billion | 7.93% |
| Short-term Investments | ₩979.26 Million | 1.37% |
| Total Liquid Assets | ₩6.64 Billion | 9.30% |
Asset Resilience Insights
- Limited Liquidity: Seoul Pharma Co. Ltd maintains only 9.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Seoul Pharma Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Seoul Pharma Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Seoul Pharma Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.53% | ₩7.54 Billion ≈ $5.11 Million |
₩71.62 Billion ≈ $48.54 Million |
-4.74pp |
| 2023-12-31 | 15.27% | ₩9.66 Billion ≈ $6.55 Million |
₩63.31 Billion ≈ $42.90 Million |
-3.52pp |
| 2022-12-31 | 18.79% | ₩11.73 Billion ≈ $7.95 Million |
₩62.43 Billion ≈ $42.31 Million |
-3.41pp |
| 2021-12-31 | 22.20% | ₩13.82 Billion ≈ $9.37 Million |
₩62.25 Billion ≈ $42.19 Million |
-0.94pp |
| 2020-12-31 | 23.14% | ₩15.06 Billion ≈ $10.21 Million |
₩65.09 Billion ≈ $44.11 Million |
+12.33pp |
| 2019-12-31 | 10.81% | ₩7.67 Billion ≈ $5.19 Million |
₩70.89 Billion ≈ $48.04 Million |
+1.72pp |
| 2018-12-31 | 9.09% | ₩8.23 Billion ≈ $5.58 Million |
₩90.57 Billion ≈ $61.38 Million |
+4.00pp |
| 2017-12-31 | 5.09% | ₩4.43 Billion ≈ $3.00 Million |
₩86.93 Billion ≈ $58.91 Million |
-5.35pp |
| 2016-12-31 | 10.45% | ₩9.67 Billion ≈ $6.55 Million |
₩92.54 Billion ≈ $62.71 Million |
+10.19pp |
| 2012-12-31 | 0.25% | ₩153.00 Million ≈ $103.69K |
₩60.68 Billion ≈ $41.12 Million |
-- |
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more